{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-122777","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.946546+00:00","generated_at":"2026-05-16T12:53:33.978286+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Neuphoria Therapeutics Announces Annual Meeting Voting Results; Elects Two Class I Directors","bullets":["Shareholders elected Peter Miles Davies (759,850 votes for) and David Wilson (758,571) as Class I directors.","Ratification of Wolf & Company P.C. as auditor passed with 807,022 votes in favor.","Non-binding advisory vote on executive compensation approved with 726,184 votes for.","On frequency of advisory votes, three years received the most votes (585,857), though non-binding.","Approximately 39.76% of outstanding shares (937,447) were represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-122777","json":"https://secwatch.observer/filing/0001213900-25-122777.json","markdown":"https://secwatch.observer/filing/0001213900-25-122777.md","text":"https://secwatch.observer/filing/0001213900-25-122777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025122777/0001213900-25-122777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390025122777/ea0270035-8k_neuphoria.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-16T12:53:33.978286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}